Importance of anti-SARS-CoV-2 assay antigenic composition as revealed by the results of the Belgian external quality assessment (EQA) scheme.
Adult
Antibodies, Viral
/ immunology
Antigens, Viral
/ immunology
Belgium
COVID-19
/ diagnosis
COVID-19 Serological Testing
/ methods
Coronavirus Nucleocapsid Proteins
/ immunology
Diagnostic Tests, Routine
Enzyme-Linked Immunosorbent Assay
Humans
Immunoglobulin A
/ immunology
Immunoglobulin G
/ immunology
Immunoglobulin M
/ immunology
Male
Phosphoproteins
/ immunology
SARS-CoV-2
/ immunology
Sensitivity and Specificity
Spike Glycoprotein, Coronavirus
/ immunology
Nucleocapsid protein
SARS-CoV-2
Spike protein
external quality assessment scheme
receptor-binding domain
serology
Journal
Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
27
07
2021
revised:
16
09
2021
accepted:
23
09
2021
pubmed:
14
11
2021
medline:
19
1
2022
entrez:
13
11
2021
Statut:
ppublish
Résumé
We report on sample IS/17575 since it generated highly divergent results in the Belgian SARS-CoV-2 serology external quality assessment scheme. Sample IS/17575 was serum originating from a 30 years old male patient. 124 diagnostic laboratories analysed this sample. A total of 168 results was returned (including 5 doubles). Overall, 38 were positive. All tests against S1 were positive except the Euroimmun IgG ELISA and the Ortho clinical Diagnostics VITROS IgG CLIA. All tests against S1/S2 (Liaison, Diasorin) resulted in a signal above cutoff. Assays against RBD, mostly generate a negative result. An exception are the Wantai SARS-CoV-2 ELISA's. All tests targeting N protein were negative. The survey shows, when >6 months post-infection, assays targeting at least S1, and preferably S1 combined with S2, are the most sensitive. This finding accentuates the necessity of external quality assessment schedules and importance of antigenic composition of serologic SARS-CoV-2 assays.
Identifiants
pubmed: 34773801
pii: S0732-8893(21)00253-4
doi: 10.1016/j.diagmicrobio.2021.115561
pmc: PMC8503966
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Antigens, Viral
0
Coronavirus Nucleocapsid Proteins
0
Immunoglobulin A
0
Immunoglobulin G
0
Immunoglobulin M
0
Phosphoproteins
0
Spike Glycoprotein, Coronavirus
0
nucleocapsid phosphoprotein, SARS-CoV-2
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115561Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The author stated that there are no conflicts of interest regarding the publication of this article.
Références
Clin Microbiol Infect. 2020 Nov;26(11):1557.e1-1557.e7
pubmed: 32745595
Infect Dis (Lond). 2021 Jul;53(7):498-512
pubmed: 33684020
Clin Chem Lab Med. 2020 Jun 25;58(7):1156-1159
pubmed: 32301750
J Microbiol Immunol Infect. 2020 Oct;53(5):821-822
pubmed: 32249185
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32350047
Clin Chim Acta. 2020 Dec;511:28-32
pubmed: 33002475
Clin Chem Lab Med. 2020 Aug 27;58(12):2121-2130
pubmed: 32853163
J Clin Virol. 2020 Aug;129:104512
pubmed: 32563180
Cell Discov. 2020 Oct 27;6:75
pubmed: 33133635
BMJ. 2020 Jul 1;370:m2516
pubmed: 32611558
J Clin Microbiol. 2021 Apr 20;59(5):
pubmed: 33574119
Am J Clin Pathol. 2020 Oct 13;154(5):610-619
pubmed: 32808976
Clin Chem. 2020 Aug 1;66(8):1107-1109
pubmed: 32484860
Clin Chim Acta. 2020 Oct;509:18-21
pubmed: 32485155
J Clin Virol. 2020 Dec;133:104663
pubmed: 33161369
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33419947
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
J Virol Methods. 2021 Feb;288:114025
pubmed: 33227340
Am J Clin Pathol. 2021 Feb 4;155(2):267-279
pubmed: 33033840
J Virol. 2021 Jan 13;95(3):
pubmed: 33144321
Science. 2020 Sep 25;369(6511):1586-1592
pubmed: 32694201
Sci Rep. 2020 Nov 18;10(1):20048
pubmed: 33208819
Isr Med Assoc J. 2020 Apr;22(4):203-210
pubmed: 32286019
Biochem Biophys Res Commun. 2021 Jan 29;538:192-203
pubmed: 33069360
Eur J Clin Microbiol Infect Dis. 2021 May;40(5):955-961
pubmed: 33236268
JAMA. 2020 Jul 14;324(2):195-197
pubmed: 32539107
Clin Chim Acta. 2020 Oct;509:1-7
pubmed: 32485157
EBioMedicine. 2020 Dec;62:103101
pubmed: 33160207
Front Mol Biosci. 2021 Apr 22;8:671633
pubmed: 33968996